Ascendis Pharma A/S Reports First Quarter 2018 Financial Results
(WorldNews Denmark)

- Continued execution and achievement of planned milestones across three wholly-owned clinical programs in rare endocrine diseases - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, May 30, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the quarter ended March 31, 2018. `Our endocrinology pipeline is moving forward with strong momentum and three wholly-owned TransCon technology product candidates in the clinic. We continue to execute on our Phase 3 program for TransCon Growth Hormone in pediatric...